SECURE-AIC Registry: Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion for Autoimmune Cytopenias



Subscribe to be notified of changes or updates to this page.

9 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The SECURE-AIC Registry is designed to capture information about SARS-CoV2 vaccine tolerance and SARS-CoV2 infections in pediatric and young adult patients (ages 0 to 21 years) living with autoimmune cytopenias (AIC) or with a recent history of autoimmune cytopenias (within the last three years). The goal of SECURE-AIC Registry is to report on outcomes of cases of COVID-19, multisystem inflammatory syndrome in children (MIS-C), and vaccine-associated changes in blood counts.

Providers caring for these patients can report all cases of SARS-CoV2 vaccination and/or COVID-19 or MIS-C to this registry, in addition to all applicable federal monitoring sites. Reporting of a case should take about 5 to 10 minutes.

With our community of providers worldwide, working together, we will be able to quickly determine the specific impact of the newly approved pediatric vaccines on patients with autoimmune cytopenias and be able to better counsel patients on safety regarding their specific concerns ("How will this affect my ITP/AIHA?"), as well as the effect of modifying therapies on responses.

Providers who actively contribute to this voluntary reporting system will help to ensure an unbiased data set.